Amphiphysin IIm Is Required for Survival of Chlamydia pneumoniae in Macrophages by Gold, Elizabeth S. et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
J. Exp. Med. 
 
©
 
 The Rockefeller University Press • 0022-1007/2004/09/581/6 $8.00
Volume 200, Number 5, September 6, 2004 581–586
http://www.jem.org/cgi/doi/10.1084/jem.20040546
 
581
 
Amphiphysin IIm Is Required for Survival of 
 
Chlamydia pneumoniae
 
 in Macrophages
 
Elizabeth S. Gold,
 
1
 
 Randi M. Simmons,
 
1
 
 Timothy W. Petersen,
 
1
 
 
 
Lee Ann Campbell,
 
2
 
 Cho-Chou Kuo,
 
2
 
 and Alan Aderem
 
1
 
1
 
Institute for Systems Biology, Seattle, WA 98103
 
2
 
Department of Pathobiology, University of Washington, Seattle, WA 98195
 
Abstract
 
Macrophages play a critical role in both innate and acquired immunity because of their
unique ability to internalize, kill, and degrade bacterial pathogens through the process of
phagocytosis. The adaptor protein, amphiphysin IIm, participates in phagocytosis and is tran-
siently associated with early phagosomes. Certain pathogens, including 
 
Chlamydia pneumo-
niae
 
, have evolved mechanisms to subvert macrophage phagosome maturation and, thus, are
able to survive within these cells. We report here that, although amphiphysin IIm is usually
only transiently associated with the phagosome, it is indefinitely retained on vacuoles con-
taining 
 
C. pneumoniae.
 
 Under these wild-type conditions, 
 
C. pneumoniae
 
 do not elicit signifi-
cant nitric oxide (NO) production and are not killed. Abrogation of amphiphysin IIm func-
tion results in 
 
C. pneumoniae–
 
induced NO production and in the sterilization of the vacuole.
The data suggest that 
 
C. pneumoniae
 
 retains amphiphysin IIm on the vacuole to survive
within the macrophage.
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Introduction
 
Chlamydia pneumoniae
 
 are obligate intracellular pathogens
that cause multiple types of respiratory tract infections and
are responsible for 10% of all cases of community-acquired
pneumonia. Exposure to this pathogen is quite common;
by age 20 yr, 50% of the population has evidence of past
infection (1). 
 
C. pneumoniae
 
 causes persistent infection in
multiple organs and may be associated with several chronic
inflammatory conditions, including atherosclerosis (2–4),
asthma (5, 6), reactive arthritis (7, 8), and Alzheimer’s dis-
ease (9). Interestingly, macrophages are the primary host
cell where 
 
C. pneumoniae
 
 are found in all of these chronic
conditions.
Macrophages play a critical role in both innate and acquired
immunity because of their unique ability to internalize and
degrade bacterial pathogens through the process of phago-
cytosis. Once internalized, the bacterium is contained in a
specialized vacuole known as a phagosome. Phagosomes are
dynamic organelles that mature over time through a series of
fusion and fission events with vesicles of the endosome/
lysosome system. Usually the terminal step in macrophage
phagocytosis is the formation of a mature phagolysosome in
which the bacterium is killed and processed for eventual
presentation to CD4
 
 
 
 T cells. Although it is understood
that several bacterial pathogens have evolved strategies to
subvert macrophage phagosome maturation and thus evade
host defense systems (10), little is known about the mecha-
nism by which this is accomplished.
We have shown previously that a novel adaptor protein,
amphiphysin IIm, is required for particle internalization
during phagocytosis (11). Amphiphysin IIm binds the
GTPase dynamin and recruits it to the nascent phagosome
(11). Deletion of the SH3 domain of amphiphysin IIm
generates a mutant protein that no longer binds dynamin,
and functions as a dominant negative inhibitor of amphiphysin
IIm activity (11). Thus, expression of AmphIIm
 
SH3
 
 
 
 in
macrophages prevents the internalization of large particles
(
 
 
 
1 
 
 
 
m) by inhibiting membrane extension around the
particle.
We report here that, although amphiphysin IIm usually
trafficks off phagosomes early in their maturation (
 
 
 
3–5
min after particle binding), it is retained on the 
 
C. pneumo-
niae
 
 vacuole for 
 
 
 
72 h and its function appears to be a crit-
ical factor in the survival of the bacterium.
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Materials and Methods
 
DNA Expression Vectors, Cell Lines, and Transfections.
 
Details
of the construction of all vectors used in this work have been de-
scribed previously (11, 12). pTIGZ2 is a bicistronic vector con-
taining a tetracycline-regulated promoter followed by a multiple
cloning site, followed by a cap-independent translational en-
hancer region and the coding region for enhanced GFP. pNeo/
Tak was constructed to direct the expression of the tetracycline
transactivator under neomycin selection. pTIGZ2-AmphIIm
 
SH3
 
 
 
allows for the coexpression of GFP and the dominant negative
form of amphiphysin IIm, in the absence of tetracycline.
The cell line RAW-TT10 is a stable line of RAW 264.7 cells
that expresses the tetracycline transactivator. In all experiments in
this paper, RAW-TT10 cells were transiently transfected by
electroporation. All experiments were performed in the absence
of tetracycline to allow for high-level expression of the trans-
fected vectors.
 
Primary Cells.
 
Murine resident peritoneal macrophages were
isolated from CD1 mice (Charles River Laboratories) and cul-
tured as described previously (13). No antibiotics were added to
any of the media used in the experiments described in this paper.
Bone marrow macrophages were also obtained from CD1 mice.
Bone marrow cells were obtained from femurs, plated in Petri
dishes in RPMI 1640 with 10% FCS and 20% L-cell media and
cultured for 5 d. The macrophages were transferred to glass cov-
erslips and used the next day for experiments.
 
Bacterial Culture and Infection. C.  pneumoniae
 
 (strain AR-39)
was cultured in HL cells and purified by density gradient centrif-
ugation (Hypaque-76; Winthrop-Breon Laboratories; reference
14). The purified organisms were resuspended in sucrose phos-
phate glutamic acid and frozen at 
 
 
 
70
 
 
 
C until use. Infectivity
was determined by direct fluorescent staining of chlamydial in-
clusions using the FITC-conjugated Chlamydia genus-specific
Mab, CF-2 (15). To determine the viability and growth of 
 
C.
pneumoniae
 
 in macrophages, the macrophages were infected at a
multiplicity of infection (MOI) of 10:1, the cells were harvested
3 d after the infection and sonicated, and the infectivity titers
were assayed in HL cells. Cells were analyzed with confocal mi-
croscopy. Inclusions were counted in 25 high-power from three
coverslips for each experiment. Data shown represent the average
from at least three separate experiments.
The viability of the macrophages before infection was deter-
mined by sorting a known number of cells expressing either
p-TIGZ2 or pTIGZ2-AmphIIm
 
SH3
 
 
 
 into 96-well plates. These
cells were lifted, and viable cell number was determined by
counting cells in the presence of trypan blue. The values ex-
pressed are corrected for input cell number.
 
Immunofluorescence, FACS, and Nitric Oxide (NO) Measurement.
 
The antiamphiphysin IIm antibody, M8D10, was generated and
characterized as described previously (13). M8D10 was detected
with either FITC or Texas red anti–rat IgG secondary antibody
(Cappel and ICN Biomedicals). Immunofluorescence and FACS
staining was performed as described previously (11, 12). Lysine
fixable dextran, which has a molecular weight of 10,000, conju-
gated to Alexa-Fluor 568 (Molecular Probes) was added to mac-
rophages at a concentration of 500 
 
 
 
g/ml for 2 h, the cells were
washed, and the dextran was chased into the macrophage lyso-
somes for 24 h before particle loading or infections. Zymosan,
 
Staphylococcus aureus
 
, and 
 
Escherichia coli
 
 were all labeled with
FITC before infections.
Nitrite concentration was measured in supernatant from mac-
rophage cultures using the Griess reagent (Molecular Probes).
 
Phagocytosis Assays.
 
Full details of the FACS phagocytosis
assay and the immunofluorescence procedure have been de-
scribed previously (12). In this work, 18 h after transfection,
RAW-TT10 cells were incubated with the indicated particles
(polystyrene “pink” particles; Spherotech, Inc.) for 10 min. The
particles were washed off with PBS, and the cells were fixed and
analyzed by flow cytometry.
Microscopy was used to confirm that the uninternalized parti-
cles were indeed being removed before analysis. RAW-TT10
macrophages were transfected, plated on glass coverslips and, after
18 h, were incubated with biotin-coated polysterene “pink” flu-
orescent beads (Spherotech, Inc.). The cells were washed and
fixed with formalin. The uninternalized beads were stained with
streptavidin conjugated to Cy5 (The Jackson Laboratory). Cells
were analyzed on a confocal microscope (Leica).
For the 
 
C. pneumoniae
 
 internalization assay, RAW-TT10 cells
were transfected with the indicated construct. 18 h later, high-
expressing cells were sorted onto coverslips using a FACStar
 
PLUS
 
.
The cells were allowed to recover for 24 h, were infected with
 
C. pneumoniae
 
 at an MOI of 10:1 for 1 h at 37
 
 
 
. Uninternalized
bacteria were removed by incubating the cells in trypsin/EDTA
for 10 min at 37
 
 
 
. The cells were fixed with formalin, permeabi-
lized with 0.25% Triton X-100 in PBS, incubated with primary
antibody (CF2 antibody) and with the secondary antibody (anti–
mouse TxR; Cappel and ICN Biomedicals), and analyzed by
FACS.
 
Transmission Electron Microscopy.
 
18 h after transfection, cells
expressing high levels of the indicated vectors were sorted into
Figure 1. C. pneumoniae vacuoles do not develop into mature phagoly-
sosomes. Bone marrow–derived macrophages were pulsed with Alexa-
Fluor 568 (red)–labeled dextran, which has a molecular weight of 10,000,
and the dextran was chased into lysosomes for 24 h. The cells were al-
lowed to ingest either (a) FITC-Zymosan, (b) FITC–S. aureus, for 2 h or
(c) C. pneumoniae (stained with FITC-CF2 antibody) for 24 h. The patho-
gens are shown in green and indicated with arrows, dextran is shown in
red, and colocalization is indicated by yellow in these merged images.
Colocalization of the internalized pathogen with dextran was determined
for 100 cells per coverslip. The data shown represent three separate exper-
iments, and the error bars reflect the standard error of the mean. 
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tissue culture dishes using a FACStar
 
PLUS
 
. The cells were infected
for 72 h, fixed with 3% glutaraldehyde (in a 0.1-M cacodylate
and 0.1-M sucrose buffer) for 1 h, and rinsed with the cacodylate
buffer. Cells were post-fixed for 1 h in 1% OsO
 
4
 
 and dehydrated
through a graded ethanol series. They were infiltrated with epoxy
resin, polymerized, and cut into 80-nM sections. These were
post-stained with 3% urnanyl acetate and lead citrate and exam-
ined on a Jeol 1200 ExII transmission electron microscope.
 
Results
 
Amphiphysin IIm Is Retained on the C. pneumoniae Vacuole.
 
Certain bacteria, including 
 
C. pneumoniae
 
, are able to survive
inside the normally hostile environment of a macrophage vac-
uole (16), and by doing so are able to set up a chronic infec-
tion. Therefore, we hypothesized that 
 
C. pneumoniae
 
 must be
able to interfere with normal macrophage phagosome matura-
tion. In fact, although other pathogens localized to dextran
positive late phagolysosomes in murine peritoneal and bone
marrow macrophages, within hours of internalization, 
 
C.
pneumoniae
 
 were almost never found in this compartment,
even 72 h after internalization (Fig. 1 and not depicted).
To identify the mechanism by which 
 
C. pneumoniae
 
evades killing by macrophages, we characterized the pheno-
type of vacuoles containing 
 
C. pneumoniae
 
 using 150 novel
antiphagosomal monoclonal antibodies (13). Using this screen,
we found that amphiphysin IIm transiently associated with
early phagosomes containing Zymosan, 
 
S. aureus
 
, or 
 
E. coli
 
was shed from these vacuoles before phagosome–lysosome
fusion, and remained absent from these vacuoles indefinitely
(Fig. 2, a, b, d, and e and not depicted). In contrast, amphi-
physin IIm was retained on the 
 
C. pneumoniae
 
 vacuole for at
least 72 h (Fig. 2, c and f). Because 
 
C. pneumoniae
 
 survives
within its vacuole, the data raised the intriguing possibility
that retention of amphiphysin IIm on the 
 
C. pneumoniae
 
 vac-
uole kept this vacuole in an immature state.
 
Macrophages Expressing AmphIIm
 
SH3
 
 
 
 Internalize C. pneu-
moniae Normally but Do Not Allow Their Growth.
 
To test
this hypothesis, we infected macrophages that expressed the
Figure 2. C. pneumoniae retain amphiphysin on their vacuole indefi-
nitely. Bone marrow–derived macrophages internalized FITC-Zymosan
for 5 min (a) or 15 min (d), FITC–S. aureus for 5 min (b) or 15 min (e),
or C. pneumoniae for 24 h (c) or 72 h (f). C. pneumoniae was visualized
with FITC-CF2. Amphiphysin was visualized with the M8D10 antibody
and an Alexa-Fluor 568 anti–rat secondary. The pathogens are shown in
green and are indicated with arrows, amphiphysin is shown in red.
Figure 3. The dependence of particle inter-
nalization on amphiphysin function varies with
particle size. (a) To ensure that uninternalized
bacteria were being removed from the surface
of the macrophages, nonpermeabilized RAW-
TT10 macrophages that had not been incubated
with C. pneumoniae (thin line), that had been
incubated with bacteria but not washed (thick
line), or that had been incubated with bacteria
and treated with trypsin-EDTA (dotted line)
were stained with the antichlamydial antibody
CF-2. (b) RAW-TT10 macrophages were
transfected with the control pTIGZ2 vector or
the AmphIImSH3  pTIGZ2 construct. 24 h after
transfection, cells expressing high levels of the
dominant negative were identified by green
fluorescence and sorted by flow cytometry. The
cells were allowed to interact with C. pneumo-
niae (MOI: 10:1) for 1 h. Macrophages that had
either not been exposed to bacteria (thin line),
or had been transfected with control vector and
infected (dotted line), or that had been trans-
fected with dominant negative amphiphysin
IIm and infected (thick line) were trypsinized,
permeabilized, and stained with CF-2 antibody.
(c) Transiently transfected RAW-TT10 macro-
phages internalized particles of the indicated size
for 10 min. Uninternalized particles were re-
moved, and the cells were analyzed by flow
cytometry. Phagocytosis is expressed as the per-
cent of highly expressing transfected cells inter-
nalizing particles relative to the percent of untransfected cells internalizing particles. Control and AmphIImSH3  cells expressing the same level of GFP
were compared. The data shown represent a minimum of three independent experiments, and error bars reflect standard error of the mean. 
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amphiphysin dominant negative mutant, AmphIIm
 
SH3
 
 
 
, in
a bicistronic vector with GFP (pTIGZ2 vector). This al-
lowed transiently transfected cells to be identified by
their green fluorescence (12, 17). Interestingly, RAW-TT10
macrophages expressing AmphIIm
 
SH3
 
 
 
 internalized 
 
C. pneu-
moniae
 
 normally (Fig. 3, a and b), suggesting that these
particles are internalized in a different way to opsonized
sheep red blood cells and Zymosan, whose internalization
required functional amphiphysin (11). This difference is
due to the small size of the bacterium because latex parti-
cles of similar size (
 
 
 
0.5 
 
 
 
m) are also internalized in the
presence of AmphIIm
 
SH3
 
 
 
, whereas larger latex particles are
not (Fig. 3 c). Cox et al. have also demonstrated that parti-
cle size governs the route of entry into macrophages (18);
large particles require the recruitment of new membrane to
the forming phagosome to provide the necessary capacity
within the vacuole.
We systematically assayed the role of amphiphysin IIm in
 
C. pneumoniae
 
 survival in macrophages. RAW-TT10 mac-
rophages expressing the dominant negative form of am-
phiphysin IIm or empty vector were infected, the cells were
lysed, and the lysate was used to infect HL cells; this rein-
fection step allowed the detection of viable 
 
C. pneumo-
niae
 
 recovered from the macrophages. We found that
AmphIIm
 
SH3
 
 
 
 inhibited 
 
C. pneumoniae
 
 growth in macro-
phages by 87% (Fig. 4 a). This confirmed our hypothesis
that retention of amphiphysin IIm on the 
 
C. pneumoniae
 
vacuole is critical for the survival of the bacteria. Transmis-
sion electron microscopy demonstrated large numbers of
 
C. pneumoniae
 
 contained within vacuoles in control macro-
phages, whereas cells expressing AmphIIm
 
SH3
 
 
 
 had vacu-
Figure 4. Amphiphysin function is critical for C. pneumoniae survival in
macrophages. (a) RAW-TT10 macrophages were transiently transfected
with either control vector or vector expressing AmphIImSH3 , and the
highest expressers were sorted using FACS®. The cells were treated with
media alone (light gray bars) or L-NMMA (dark gray bars) overnight, in-
fected with C. pneumoniae for 72 h, and lysed; the lysate was used to infect
HL cells. 72 h after the second infection, the HL cells were stained with
the CF2 antibody. Inclusions were counted on 25 high-power fields from
three coverslips for each experiment. The data represent the average from
at least three separate experiments, and the error bars represent standard
error of the mean. (b) Transiently transfected RAW-TT10 macrophages
were sorted, infected, and analyzed by transmission electron microscopy.
The left panel shows a typical cell expressing the vector control and the
right panel shows a typical cell expressing AmphIImSH3 .
Figure 5. NO production correlates with vacuolar sterilization. (a) RAW-
TT10 macrophages were transfected with vector alone (light gray bars) or
plasmid-expressing AmphIImSH3  (dark gray bars), and highly expressing
cells were sorted using FACS. The cells were allowed to internalize the
indicated particles. 72 h later, NO production was assayed using the
Griess reagent. The experiment was repeated four times, and the data are
from a typical experiment and represent the average of triplicate samples.
The error bars are standard error of the mean. (b) Transfection and sorting
was performed as detailed before. The cells were infected with C. pneu-
moniae for 72 h and exposed to the indicated particles for an additional
72 h. NO production was assayed using the Griess reagent. The experi-
ment was repeated three times, and the data are from a typical experiment
and represent the average of triplicate samples. The error bars are stan-
dard error of the mean. 
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oles containing remnants of the bacteria with few 
 
C. pneu-
moniae
 
 visible (Fig. 4 b). Pretreatment of the cells with
L-NMMA, an inhibitor of NO, partially rescued 
 
C. pneu-
moniae
 
 survival in AmphIIm
 
SH3
 
 
 
-expressing cells (Fig. 4 a),
suggesting that at least some of the killing is due to induc-
tion of NO in these cells. Interestingly, 
 
C. pneumoniae
 
 did
not elicit significant NO production from control mac-
rophages, whereas 
 
S. aureus
 
 and Zymosan did (Fig. 5 a).
However, when amphiphysin function was inhibited, the
cells produced high levels of NO after infection with 
 
C
 
.
 
pneumoniae
 
, and this correlated with sterilization of the vac-
uole (Fig. 5 a). There was no difference in Zymosan and 
 
S.
aureus
 
 elicited NO production in control cells and cells ex-
pressing dominant negative amphiphysin IIm (Fig. 5 a). Al-
though control macrophages did not produce NO in re-
sponse to 
 
C. pneumoniae
 
 infection, this was not due to a
general inhibition of NO production because these cells
produced high levels of NO upon exposure to 
 
S. aureus
 
 or
Zymosan (Fig. 5 b).
 
Discussion
C. pneumoniae are able to establish persistent infections in
multiple organ systems and this appears to contribute to
several chronic diseases, including atherosclerosis, chronic
pulmonary disease, and arthritis (2–8). In all of these condi-
tions, the bacteria are found surviving and replicating in
the normally hostile environment of macrophage vacuoles.
Therefore, we hypothesized that C. pneumoniae are able to
subvert macrophage phagosome maturation, and we show
here a role for amphiphysin in this process. We demon-
strated previously that amphiphysin IIm is recruited to na-
scent phagosomes, where it regulates the insertion of mem-
brane (11). Usually, the molecule trafficks off phagosomes
soon after particle internalization, but in the case of C.
pneumoniae it remains on the vacuole indefinitely, and this
is critical for the bacteria’s survival.
Amphiphysin has numerous roles in membrane traffick-
ing. Initially, it was shown to be critical in receptor
mediated endocytosis; the NH2-terminal domain of am-
phiphysin interacts with clathrin, whereas its COOH-ter-
minal SH3 domain interacts with the proline-rich domain
of dynamin (19, 20). This results in the targeting of dy-
namin to forming endosomes, which is necessary for scis-
sion of the endosome from the plasma membrane (21).
More recent work has demonstrated that amphiphysin also
has roles in exocytosis (22, 23) and intracellular vesicular
trafficking (24). Amphiphysin also appears to have a direct
effect on membrane deformation and curvature (25, 26). In
addition to its general role in regulating membrane traffic,
we and others have also demonstrated that amphiphysin has
a role in phagosome maturation by controlling membrane
insertion into the forming phagosome (11, 27). This func-
tion of the molecule appears to be related to its capacity to
activate dynamin and recruit PI-3 kinase (11). In turn, PI-3
kinase has a central role in regulating membrane traffic
(28). Thus the role for amphiphysin in membrane traffic is
unequivocal, and it is reasonable to postulate that its cap-
ture on the immature phagosome is the underlying reason
why the chlamydial vacuole does not progress to a fully
fledged phagolysosome where effective killing of the bacte-
rium can occur.
It has been demonstrated recently that a related Chlamy-
dia species, Chlamydia trachomatis, is able to survive in mac-
rophages and that this was reversed by the activation of
phospholipase D (29). Amphiphysin is known to bind di-
rectly to phospholipase D and inhibit its activity by doing
so (30); it is possible that by retaining amphiphysin on its
vacuole, C. pneumoniae may inhibit phospholipase D activ-
ity and promote its own survival.
The precise mechanism by which amphiphysin prevents
chlamydial killing is not fully elucidated, but it does appear
to involve the induction of inducible NO synthase. Macro-
phage production of NO is known to play a key role in
host defense against a wide variety of pathogens including
Mycobacterium tuberculosis, Leishmania major, Listeria monocto-
genes, and Toxoplasma gondii (31). NO also has an important
role in control of C. pneumoniae infection as evidenced by
the observation that inducible NO synthase    mice have
increased susceptibility to respiratory infection with these
bacteria (32), and are more susceptible to C. pneumoniae in-
duced exacerbation of atherosclerotic lesions (33).
We demonstrate here that macrophages produce very
little NO when they internalize C. pneumoniae. However,
when amphiphysin function is abrogated, C. pneumoniae
provokes robust NO production and this correlates with
sterilization of the vacuole. C. pneumoniae does not globally
disable the machinery necessary for NO production, as in-
fected macrophages are still able to produce NO when ex-
posed to a second stimulus.
Together, our data suggest that by retaining functional
amphiphysin IIm on the vacuole, C. pneumoniae are able to
prevent vacuole maturation, thereby avoiding the detection
mechanisms that activate NO production.
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